<DOC>
	<DOCNO>NCT00752518</DOCNO>
	<brief_summary>The purpose study assess safety/tolerability determine Japanese recommend dose ( RD ) bortezomib administer once-daily intravenous bolus twice weekly 2 consecutive week ( Days 1 , 4 , 8 , 11 ) follow 10-day rest period ( Days 12 21 ) Japanese patient relapse refractory multiple myeloma .</brief_summary>
	<brief_title>A Japan Phase I/II Study Bortezomib Relapsed Refractory Multiple Myeloma Patients</brief_title>
	<detailed_description>In Japan , clear treatment guidance patient multiple myeloma repeatedly relapse become refractory . At present , various therapy include multi-drug combination chemotherapy , hematopoietic stem cell transplantation , corticosteroid massive therapy , interferon therapy , thalidomide therapy , radiation therapy experimental therapy conduct exploratory salvage therapy find one patient show response . Considering antitumor activity JNJ-26866138 relapse refractory MM clear tolerability acceptable base result overseas clinical study , development JNJ-26866138 Japan quite meaningful . This non-randomized , open-label , multicenter dose-escalation study consist two part : Phase I part intend intravenously administer JNJ-26866138 twice daily 2 week ( Days 1 , 4 , 8 , 11 ) establish Japanese RD base incidence dose limit toxicity ( DLTs ) , Phase II part intend evaluate efficacy safety JNJ-26866138 patient repeatedly treat Japanese RD . Based body surface area calculate treatment cycle , dose calculate patient accord dose level specify Patient Enrollment Center ( 0.7mg/m2 , 1.0 mg/m2 1.3 mg/m2 ) . JNJ-26866138 intravenously administer daily , twice weekly 2 week ( Days 1 , 4 , 8 , 11 ) , follow 10-day rest period ( Days 12 21 ) . This consider one cycle ( 21 day ) , treatment repeat 6 cycle patient expect show response .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients diagnose multiple myeloma base predetermine diagnostic criterion Patients receive least standard firstline therapy documentation failure therapy relapse remission currently require therapy progressive disease ( PD ) assess investigator ( subinvestigator ) enrollment . There limitation number prior therapy ( salvage therapy Number regimen ) Patients measurable disease , define follow : Secretory Multiple myeloma : Quantifiable serum monoclonal protein value ( general , serum M protein value &gt; = 1.0 g/dL IgG &gt; = 0.5 g/dL IgA . ) , When M protein excrete urine , M protein quantitatively assayable urinary protein electrophoresis ( general , urinary M protein excretion &gt; = 0.2g/day. ) . Nonsecretory Multiple myeloma : Presence bidimensionally measurable soft tissue mass ( plasmacytoma ) long diameter 2cm determine applicable radiography ( i.e . MRI , CTscan ) Patients life expectancy &gt; = 3 month initiation JNJ26866138 therapy Patients Karnofsky Performance Status ( PS , general condition ) &gt; = 60 Patients age &gt; =20 = &lt; 75 enrollment study Patients hospitalize least initial treatment study drug completion Cycle 1 ( include 10day observation period JNJ26866138 injection next cycle delay `` condition start nextcycle '' satisfy , patient must hospitalize patient satisfies criterion ( possible transfer patient treatment outpatient basis next cycle delay due reason schedule adjustment Patients plasma cell leukemia ( Definition plasma cell leukemia : A state proportion plasma cell peripheral blood 20 % , absolute count 2x10 ^ 9L . ) Patients CrowFukase syndrome ( multiple neuritis , pigmentation , endocrine disorder , swollen organ , sclerotic bone lesion , etc . ) Patients peripheral sensory neuropathy Grade 2 worse ( `` neuropathy sensory '' NCICTC Japanese translation JCOG version 2 ) neuropathic pain Grade 2 worse ( `` neurologic pain '' NCICTC Japanese translation JCOG version ) Patients underwent allogeneic hematopoietic stem cell transplantation Patients underwent two consecutive course autologous peripheral blood stem cell transplantation ( tandem transplantation , etc . ) Patients suspected cardiac amyloidosis ( patient leave ventricular ejection fraction ( LVEF ) less 55 % echocardiogram ) Patients active infection ( fever .38ÂºC ) Patients clinical finding pneumonia ( interstitial pneumonia ) pulmonary fibrosis bilateral abnormal interstitial shadow ( example , groundglass opacity , linear opacity ) chest CT ( high resolution CT ) , regardless presence absence associate symptom ( consultation specialist respiratory system field hold necessary ) Patients heart disease Class III IV New York Heart Association ( NYHA ) cardiac function classification , patient myocardial infarction within 6 month prior screen , patient uncontrolled angina pectris , serious ventricular arrhythmia , acute ischemia , active conduction disorder , others Patients renal disease ( chronic glomerulonephritis , diabetic nephropathy , hypertensive nephropathy , gouty nephropathy , etc . ) lead onset impaired renal function Patients uncontrolled hypertension Patients pharmacotherapy ( oral hypoglycemic drug insulin preparation ) diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>bolus</keyword>
	<keyword>intravenous</keyword>
	<keyword>proteasome inhibitor</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>refractory</keyword>
	<keyword>relapse</keyword>
</DOC>